Positron Emission Tomography Radiopharmaceuticals
TABLE G-1 Positron Emission Tomography Radiopharmaceuticals
| Trade Name | Radiopharmaceutical | Clinical Indication |
|
Ammonia N13 |
13N-Ammonia |
Myocardial blood flow |
|
Cardio-Gen |
82Rb-Rubidium chloride |
Myocardial blood flow |
|
Florbetapir F18 ** |
18F-styryl-pyridine |
Amyloid Plaques Alzheimer’s disease |
|
Fluorbetabane F18# |
18F-styryl-pyridine |
Amyloid Plaques Alzheimer’s disease |
|
Flutemetamol F18# |
18F-hydroxy-benzothiazole |
Amyloid Plaques Alzheimer’s disease |
|
Fluorpiridaz F18# |
18F-pyridazinone |
Myocardial blood flow |
|
Fludeoxyglucose F18 Injection |
18F-Fluorodeoxyglucose |
Oncology,Myocardial Viability, Seizure Foci |
|
Sodium Fluoride F18 |
Sodium 18F-fluoride |
Bone scans |
| Single Photon Emission Computed Tomography (SPECT) Radiopharmaceuticals | ||
|
Chromitope Mallinkrodt Cr-51 |
Sodium 51Cr-chromate |
Red Blood Cell Labeling |
|
Ga-67 |
67Ga-Gallium citrate |
Soft tissue tumor, Inflammatory processes |
|
Indium In 111 oxyquinoline |
111In-Indium oxyquinoline |
Luekocyte and platlet labeling |
|
MPI Indium DTPA In 111 |
111In-Indium Pentetate disodium |
Cerebrospinal fluid kinetics |
|
ProstaScint |
111In-Indium Capromab Pendetide |
Prostate Tumor |
|
Octreoscan |
111In-Indium Pentetreotide |
Neuroendocrine tumors Gastroenteropancreatic tumors |
|
Zevalin |
111In -Ibitumonmab iuxetan |
non-Hodgkin’s lymphoma |
|
Sodium Iodide I 123 |
Sodium 123I-iodide |
Thyroid uptake |
|
Datscan |
123I-Ioflupane |
Striatal Dopaminae Transporters |
|
Adreview |
123I-Iobenguane |
Pheochromacytoma, Neuroblastoma |
|
Glofil |
125I-Iothalamate |
Glomerular filtration measurement |
|
Jeanatope |
125I-human Serum Albumin |
Total blood and plasma volume |
|
Megatope |
131I-human Serum Albumin |
Total blood and plasma volume |
|
Bexxar |
131I-Tositumomab |
non-Hodgkin’s lymphoma |
|
Sodium Iodide I 123 |
Sodium 123I-iodide |
Thyroid uptake |
|
Technetium Generator |
99mTc-Pertechnetate |
Thyroid, salivary and parathyroid |
|
Technelite |
glands, ectopic gastric mucosa, |
|
|
Ultra-Technekow FM |
dacryocystography, cystography |
|
|
Neurolite |
99mTc-Bicisate (ECD) |
Cerebral Perfusion |
|
Hepatolite-CIS |
99mTc-Disofenin (DISIDA) |
Hepatobiliary function |
|
Ceretec |
99mTc-Exametazine (HMPAO) |
Cerebral Perfusion |
| Trade Name | Radiopharmaceutical | Clinical Indication |
|
Pulmolite |
99mTc-Aggregated albumin |
Pulmonary Perfusion |
|
Technetium Tc 99M Albumin Aggregated Kit |
||
|
Choletec |
99mTc-Mebrofenin |
Hepatobiliary function |
|
Osteolite |
99mTc-Medronate (MDP) |
Bone imaging |
|
Technescan MAG3 |
99mTc-Mertiatide |
Renal function |
|
Techneplex DTPA |
99mTc-Pentetate |
Renal function, Radioaresol ventilation |
|
Phosphotec Pyrolite Pyro Technescan PYP Amersham PYP |
99mTc-Pyrophosphate (PYP) |
Infarct imaging, in vivo Red blood cell labeling |
|
Cardiolite Miraluma |
99mTc-Sestamibi |
Myocardial blood flow, Breast tumor |
|
DMSA |
99mTc-Succimer (DMSA) |
Renal function |
|
Sulfur Colloid |
99mTc-Sulfur Colloid |
Liver/spleen gastric emptying, GI bleeds |
|
AN-Sulfur Colloid |
||
|
Myoview |
99mTc-Tetrofosmin |
Myocardial blood flow |
|
Thallium |
201Tl-Thallium chloride |
Myocardial blood flow, Parathyroid, Tumor |
|
Xenon |
133Xe-xenon gas |
Pulmonary ventilation |
| Radiotherapeutics | ||
|
Zevalin |
90Y-Ibitumonmab Tiuxetan |
non-Hodgkin’s lymphoma |
|
Bexaar |
131I-Tositumomab |
non-Hodgkin’s lymphoma |
|
Metastron |
89Sr-strontium |
bone pain from skeletal metastases |
|
Quadramet |
153Sm Lexidronin |
bone pain from skeletal metastases |
|
Sodium Iodide I 131 |
Sodium 131I-iodide |
Thyroid therapy |
|
HICON |
||
|
Phosphocol 32 |
32P-Chromicphosphate |
Intracavity malignancies |
** Conditionally approved by the FDA
# in Phase 3 clinical trials
SOURCE: NRC/IOM 2007; FDA 2011; UAMS 2011
REFERENCES
FDA (U.S. Food and Drug Administration). 2011. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration [online]. Available: http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm [accessed November 21, 2011].
NRC/IOM (National Research Council and Institute of Medicine). 2007. Appendix C. Commercially available radiopharmaceuticals. Pp. 151-154 in Advancing Nuclear Medicine through Innovation. Washington, DC: The National Academies Press.
UAMS (University of Arkansas for Medical Sciences). 2011. Radiopharmaceutical List and Package Inserts. Nuclear Pharmacology, College of Pharmacy, University of Arkansas for Medical Sciences [online]. Available: http://nuclearpharmacy.uams.edu/resources/PackageInserts.asp [accessed October 24, 2011].